Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Ligand Pharmaceuticals (LGNDZ) EBIT Margin (2016 - 2025)

Ligand Pharmaceuticals (LGNDZ) has disclosed EBIT Margin for 16 consecutive years, with 23.2% as the latest value for Q4 2025.

  • Quarterly EBIT Margin rose 4571.0% to 23.2% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 15.29% through Dec 2025, up 2882.0% year-over-year, with the annual reading at 15.29% for FY2025, 2882.0% up from the prior year.
  • EBIT Margin hit 23.2% in Q4 2025 for Ligand Pharmaceuticals, down from 47.58% in the prior quarter.
  • In the past five years, EBIT Margin ranged from a high of 66.82% in Q4 2021 to a low of 79.89% in Q1 2025.
  • Historically, EBIT Margin has averaged 7.17% across 5 years, with a median of 9.88% in 2021.
  • Biggest five-year swings in EBIT Margin: tumbled -10671bps in 2022 and later skyrocketed 6372bps in 2025.
  • Year by year, EBIT Margin stood at 66.82% in 2021, then plummeted by -160bps to 39.89% in 2022, then soared by 70bps to 11.95% in 2023, then tumbled by -88bps to 22.51% in 2024, then surged by 203bps to 23.2% in 2025.
  • Business Quant data shows EBIT Margin for LGNDZ at 23.2% in Q4 2025, 47.58% in Q3 2025, and 17.73% in Q2 2025.